Diagnosis and Management of Advanced Hepatocellular Carcinoma CME

Author Information and Disclosures

Release Date: May 30, 2008; Valid for credit through May 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Bayer, Onyx
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Review the risk factors for HCC and the challenges associated with treatment
  2. Describe curative treatment for patients with HCC and the advantages/disadvantages associated with each treatment approach
  3. Compare and contrast currently used systemic agents for the treatment of patients with advanced HCC
  4. List the molecular pathways that serve as therapeutic targets in patients with HCC
  5. Review current data on emerging targeted therapies for patients with HCC
Authors and Disclosures

Andrew X. Zhu, MD, PhD
Disclosure: Andrew X. Zhu, MD, PhD, has disclosed that he has served as an advisor or consultant to Genentech and Bayer.


Gregory J. Gores, MD
Disclosure: Gregory J. Gores, MD, has disclosed that he is a consultant for Bayer, Centocor Research and Development, Conatus Pharmaceuticals, Human Genome Sciences, Intercept Pharmaceuticals, Pfizer, Schering, and ViroBay. He has also disclosed that he serves on the editorial boards of the American Journal of Physiology, Journal of Clinical Investigation, American Journal of Gastroenterology, Nature Reviews in Clinical Gastroenterology, Journal of Hepatology, and Liver Transplantation.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.


John F. Kross, DDS
Disclosure: John F. Kross, DDS, has disclosed no relevant financial relationships.

 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.